Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Dec 2021 · 1 min read
In brief
In brief
This retrospective study examines chemotherapy-induced thrombocytopenia (CIT) in 42 Ewing sarcoma patients, finding that 64% experienced CIT primarily during consolidation therapy with ifosfamide/etoposide. Ten patients received romiplostim with dose-dependent platelet recovery and minimal adverse effects, suggesting potential for maintaining dose-dense treatment intensity.
Written by the GCMD Library team from the article.
Statements in this article
Maintaining dose-dense, interval-compressed chemotherapy improves survival in patients with Ewing sarcoma but is limited by myelosuppression.
Chemotherapy-induced thrombocytopenia was defined as a failure to achieve 75,000 platelets per microliter by day 21 after the start of any chemotherapy cycle.
Twenty-seven out of 42 patients (64%) developed isolated chemotherapy-induced thrombocytopenia, delaying one to four chemotherapy cycles per patient.
Chemotherapy-induced thrombocytopenia occurred during consolidation therapy in 24 of 27 patients (88.9%).
Chemotherapy-induced thrombocytopenia occurred with ifosfamide/etoposide cycles in 24 of 27 patients (88.9%).
Univariate analysis failed to identify risk factors for chemotherapy-induced thrombocytopenia.
The use of radiation approached significance as a risk factor for chemotherapy-induced thrombocytopenia (p-value = .056).
The median starting dose of romiplostim was 3 μg/kg (range 1-5).
Romiplostim doses were escalated weekly by 1-2 to 4-10 μg/kg and continued throughout chemotherapy.
A higher romiplostim dose was associated with a higher change in average platelet counts from baseline, r = .73 (p = .04).
No romiplostim-related adverse events were identified aside from mild headache.
Chemotherapy-induced thrombocytopenia is the primary reason for the inability to maintain treatment intensity in Ewing sarcoma.